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Abstract
Background: In the last couple of years, schizophrenia was often discussed as autoimmune disease. Several antibodies
were suspected, but so far there has been no proof of Gamma-aminobutyric acid (GABA) receptor antibodies in
patients with schizophrenia.
Case presentation: In this case report we present a 21-year old woman with schizophrenic symptoms, who showed
anti-GABAB1 antibodies when screened by a vast recombinant neurology mosaic on Human Embryonic Kidney Cells
293 (HEK293) cells. The young woman presented with various psychotic symptoms as well as speech and motor ataxia,
with the neurological signs starting in childhood.
Conclusion: A hypofunction of the GABAergic system is a possible cause of severe schizophrenic symptoms.
Postmortem studies proved this hypothesis by showing dysfunctional GABAergic interneurons in various brain
areas. Therefore one should always think of an immune-mediated pathogenesis as well memory impairment and
behavioral changes co-occur with frequent seizures.
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Background
Schizophrenia is a severe polygenic and heterogeneous psy-
chiatric disease with onset in early adulthood. According to
the Diagnostic and Statistical Manual of Mental Disorders
schizophrenia is characterized by profound disruption in
cognition and emotion, psychotic manifestations and nega-
tive symptoms. The causes of schizophrenia have been the
subject of much debate and the underlying pathome-
chanism remains so far unknown [1]. Intrinsic inflam-
matory and immunologic processes without sufficient
repair mechanisms seem to be involved [2].
Glutamate is a key player in the mediation of schizo-
phrenic symptoms and by non-competitively antagoni-
zing the glutamate N-methyl-D-aspartate (NMDA)
receptor with substances such as ketamine, phencyc-
lidine, or Dizocilpine (MK-801) in animals [3], neurological
and psychiatrics symptoms similar to those in humans can
be produced. They comprise positive (hallucinations, delu-
sions, thought disorder) and negative (anhedonia, blunted
affect, avolition) symptoms of schizophrenia, as well as
movement dysfunction, autonomic instability and seizures
[4]. The described psychomimetic effects of NMDA antag-
onists have been attributed to pre-synaptic functional re-
ceptor blocking in thalamus and frontal cortex, causing a
decreased Gamma-aminobutyric acid (GABA) release [5].
GABA has a major inhibitory function in the central ner-
vous system and modulates neuronal activity and working
memory via inhibitory prefrontal neurons. There are three
GABA receptor types (A, B, C), of which GABAB is a G-
protein coupled transmembrane receptor consisting of two
subunits (B1, B2). Subunit B1 is responsible for the trans-
mitter binding as well as for the general receptor function,
whereas B2 ensures the transmembrane localization and
the G-protein activation. A direct antagonistic binding to
the GABA receptors (GABAR) and dysfunctional inhibitory
cascade could imitate the same schizophrenic symptoms as
a decreased level of the transmitter GABA itself.
The role of GABAR has already been shown in
several immunohistochemical experiments in which
reduced immunolabeling of GABAR subunits occurred in
different brain regions (hippocampus, prefrontal cortex,
inferior temporal cortex, and entorhinal cortex, lateral
cerebellum) of schizophrenic patients [6, 7].
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In case of a GABAB receptor antibody mediated enceph-
alitis patients usually present with a classical limbic en-
cephalopathy with seizures. Magnetic Resonance Imaging
(MRI) findings typically show an increased signal in the
medial temporal lobes, and Cerebrospinal Fluid (CSF)
shows an elevated lymphocyte cell count. The animal
model of GABAB receptor antagonism resulted in similar
symptoms such as seizures, memory deficits, anxiety, and
affective dysregulation in rodents [8]. Lancaster et al.
assessed and serologically screened 15 patients with sus-
pected paraneoplastic or immune-mediated encephalitis
as well as 104 controls for neuronal antibodies with a
transfected HEK293 assay. Anti-GABAB1 antibodies were
found in all patients and half of them had tumors, mainly
small cell lung cancer [9]. However anti-GABAB receptor
encephalitis also develops without cancer association and
resembles other central synaptic autoimmunities. The
presence of CSF antibodies in patients with both neuro-
logical and psychiatric deficits has been examined [10, 11].
Whereas anti-GABAB receptor antibodies were frequently
found in previously seronegative patients with encephalitis
and small cell lung cancer, they did not occur in patients
with isolated cerebellar ataxia [10].
Case presentation
The 21 year old woman was admitted to our psychiatric
ward as an emergency for the first time in 2010, report-
ing hallucinatory voices as well as persistent visual hallu-
cinations (command to jump out of the window, blood
running down the walls) and tried to harm herself by re-
peatedly smashing her head against the wall. Moreover,
she demonstrated psychomotor agitation and suffered
from alcohol intoxication with 1.98 promille. The psych-
otic symptoms remained after detoxication and the pa-
tient reported to have suffered from negative symptoms
such as apathy and depressed mood during the previous
six months. The patient was diagnosed with paranoid
schizophrenia according to the international classifica-
tion of disease (ICD-10), which is commonly used in
clinical routine as well as psychiatric research. During
the following three months the patient was admitted
two more times, always in a floridly psychotic state with
self-inflicted injuries and intoxicated with alcohol. Anti-
psychotic treatment comprised ziprasidone and quetia-
pine with no satisfactory effect. The patient was treated
with ziprasidone only for a couple of weeks and in a low
dose. Continuous was with quetiapine for almost two
years in an initial dose of 500 mg and a maintenance
dose of 100 mg daily, both without considerable effect.
Dosage was reduced due to the patient’s pregnancy.
The patients’ first psychiatric contact occurred 2004
at the age of 14, when she was brought to a child psych-
iatrist because of unstable interpersonal relationships,
self-consciousness, identity, and behavior difficulties.
Auto-aggressive tendencies started at the age of 12.
Because of acute distress, difficult adjustment to social
situations and somatic manifestations, three more hos-
pital admissions to child and adolescent psychiatry be-
came necessary subsequently, all lasting but a few days.
According to her mother the patient was delayed in
speech and motor skills and attended a school for learning-
disabled children. At the time of consultation, a psycho-
motor retardation was still evident. The patient complained
of frequent headaches. The findings of the neurological
exam indicated an ataxia in speech (dysarthria) as well as
motor coordination. In pediatric physical assessment som-
atosensory evoked potentials (SEP) recording (N. tibialis)
and electromyography (EMG) (M. tibialis anterior) were
normal, electroencephalography (EEG) was normal ac-
cording to age. Brain MRI and angiography did not show
any space-occupying lesion or vascular malformation.
There were no detectable alterations of the purine and
pyrimidine metabolism and electrophoresis of lipoproteins
did not reveal any pathological results either.
One sample of serum was collected and serum was
isolated by centrifugation (2500 x g/ 10 min) and kept
at −80 °C until completion of recruiting phase. Serum
was subsequently sent for diagnostic workup to the
authors’ lab (Luebeck, Germany), and tested for the
presence of antineuronal antibodies by means of a commer-
cial immunofluorescence assay (Autoimmune Encephalitis
Mosaic, Euroimmun, Luebeck, Germany).
Slides were incubated with patient samples at a start-
ing dilution of 1:10. After incubation for 30 min at room
temperature, the slides were rinsed with a flush of Phos-
phate Buffered Saline (PBS)-Tween and incubated in
PBS-Tween for at least 5 min. Bound antibodies were
labelled using Fluorescein-conjugated goat anti-human
immunglobulines IgG, IgA or IgM antibodies for 30 min
and washed as described before. Samples were classified
as positive or negative based on the intensity of surface
immunofluorescence of transfected cells in direct com-
parison with non-transfected cells and control samples.
Central nervous system (CNS) tissues were assessed for
the presence of characteristic staining patterns indicative
of the presence of antibodies against neuropil or other
neuronal antigens in the patient’s sample. In a dilution
of 1:320 the patient’s serum still showed antibody binding
to GABAB surface antigen in the assay (Fig. 1).
The patient refused plasmapheresis to remove the
antibodies. Further diagnostic including CSF samples (to
confirm the presence of receptor antibodies) and chest
x-ray (to rule out a Small Cell Lung Cancer (SCLC))
were not performed for ethical reasons, since the patient
accidentally got pregnant.
The Ruhr-University Bochum ethics committee ap-
proved the analysis (3250–08), and written informed
consent was obtained from the patient.
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Conclusions
Several auto-antibodies against neurotransmitters and
their receptors (such as antiserotonin, antinicotinic
and antimuscarinic receptor antibodies) have been
found in serum or CSF of schizophrenic patients,
thus suggesting an autoimmune etiological connection
[12]. Anti-dopaminergic receptor antibodies or inhibition
of the transmitter itself do not seem relevant [13], but the
GABAergic control of this dopaminergic system seems
an important factor in the course of schizophrenia
[14]. A hypofunction of the GABAergic system is a
possible cause of severe schizophrenic symptoms.
Postmortem studies proved this hypothesis by show-
ing dysfunctional GABAergic interneurons in various
brain areas [15]. Therefore one should always think
of an immune-mediated pathogenesis as well memory
impairment and behavioral changes co-occur with
frequent seizures. The prevalence of anti-GABAB1
antibodies in clinically defined tested cohorts (limbic
encephalopathy) was 0.14 and 0–0.04 in healthy and
illness cohorts respectively [9, 16].
So far there has been no proof of GABA receptor anti-
bodies in patients with schizophrenic symptoms. In this
case report we presented a young woman with schizo-
phrenic symptoms, who was screened by a vast recom-
binant neurology mosaic on HEK293 cells and showed
anti-GABAB1 antibodies. The young woman presented
with various psychotic symptoms as well as speech and
motor ataxia.
The clinical coexistence of neurological and psychi-
atric features in patients with encephalitis has been
known for quite some time, but recently cell surface
antibodies have been found in patients with so far purely
psychiatric symptoms. For example, specific receptor anti-
bodies (anti- Voltage-gated potassium channel complex
(VGKC), anti-N-methyl-D-aspartate receptor (NMDAR),
anti-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR)) were found in (young) patients
with first episodes of psychotic symptoms [17, 18]. In
some cases of clinical evident schizophrenia autoanti-
bodies to cell surface antigens such as the GABAB recep-
tor might emerge. In these cases, further diagnostics to
rule out a tumor or another infection have to been under-
taken, since symptoms may regress under immunotherapy
or tumor removal.
The current case is only a single description of an as-
sociation in a patient that was not neurologically treated.
There can therefore be no conclusion about the general
relevance of these antibodies in schizophrenia, but the
need for screening further patients is evident.
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Fig. 1 HEK cells co-transfected (above) and non-transfected (below) with
cDNA for GABA receptor (B1). Serum of patient bound to the surface of
cells transfected with GABARs, Antibody titre 1:320, Irani Score 2
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